What is the most common infection associated with IUCD use?
If a patient misses oral contraceptive pills for 10 consecutive days, what is the most appropriate management?
What is the most common complication following intrauterine device insertion?
The use of a levonorgestrel-releasing intrauterine contraceptive device is helpful in all of the following conditions except:
The "Calendar method" of family planning was described by whom?
Oral contraceptive pills cause all the following side effects except:
Which of the following is NOT a method used for laparoscopic sterilization?
All of the following are indications for using mifepristone (RU 486), EXCEPT?
Which intrauterine contraceptive device (IUCD) is associated with the highest incidence of ectopic pregnancy?
Which of the following is NOT a long-acting reversible contraception?
Explanation: **Explanation:** The relationship between Intrauterine Contraceptive Devices (IUCDs) and infection is a high-yield topic for NEET-PG. While the risk of Pelvic Inflammatory Disease (PID) is primarily elevated only during the first 20 days following insertion (due to the introduction of vaginal flora into the sterile uterine cavity), the most common causative organisms are those responsible for sexually transmitted infections. **Why Chlamydia is Correct:** **Chlamydia trachomatis** is the most common organism associated with IUCD-related infections and PID in general. The IUCD itself does not cause infection but can facilitate the "wicking" or ascending spread of pre-existing cervical pathogens into the upper reproductive tract. Chlamydia is frequently asymptomatic, leading to subclinical PID and subsequent tubal factor infertility. **Analysis of Incorrect Options:** * **Staphylococcus epidermidis:** This is a common skin commensal. While it can cause infections in prosthetic heart valves or shunts, it is not a primary pathogen in the female genital tract or associated with IUCDs. * **Staphylococcus aureus:** While it can cause various systemic infections, it is specifically associated with **Toxic Shock Syndrome (TSS)** in tampon users, rather than routine IUCD-related PID. * **Group D Streptococcus (Enterococci):** These are part of the normal enteric flora. While they can be involved in polymicrobial pelvic infections, they are significantly less common than Chlamydia. **Clinical Pearls for NEET-PG:** * **Actinomyces israelii:** If the question asks for the organism specifically associated with **long-term** IUCD use (showing "sulfur granules" on Pap smear), the answer is Actinomyces. * **Timing:** The risk of infection is highest in the **first 3 weeks** post-insertion. If PID occurs after this window, it is usually due to a newly acquired STI rather than the IUCD itself. * **Management:** In mild-to-moderate PID, the IUCD does **not** need to be removed immediately; treatment can begin with the device in situ.
Explanation: ### Explanation **Correct Answer: C. Continue the pills and use an additional form of contraception** **Underlying Medical Concept:** The primary mechanism of Combined Oral Contraceptive Pills (COCPs) is the suppression of ovulation via the inhibition of FSH and LH. When pills are missed for more than **2 consecutive days** (especially in the first week or for a duration as long as 10 days), the hypothalamic-pituitary-ovarian axis escapes suppression. This leads to follicular development and a high risk of "escape ovulation." Management requires restarting the hormonal suppression immediately to prevent further follicular growth while simultaneously using a **barrier method (back-up contraception)** for at least **7 days** of continuous pill intake to ensure ovulation is once again suppressed. **Why Incorrect Options are Wrong:** * **Option A:** Stopping the pills for 7 days would further increase the "pill-free interval," leading to a certain rise in FSH levels and imminent ovulation, significantly increasing the risk of pregnancy. * **Option B:** Continuing as usual without backup is unsafe. After a 10-day gap, the contraceptive efficacy is lost, and the patient is no longer protected. * **Option D:** Taking a single additional pill is insufficient to compensate for a 10-day lapse. This strategy is only applicable for 1 missed pill (where the patient takes 2 pills on the day she remembers). **High-Yield Clinical Pearls for NEET-PG:** * **The "7-Day Rule":** It takes 7 days of continuous active pills to reliably suppress ovulation. If >2 pills are missed, backup (condoms) is mandatory for 7 days. * **Emergency Contraception (EC):** If pills were missed in the **first week** of the pack and unprotected intercourse occurred during the gap, EC should be considered. * **Missed Pill Protocol (WHO):** * **1 Pill missed:** Take as soon as remembered; no backup needed. * **2 or more Pills missed:** Take the most recent missed pill + continue the pack + **7 days of backup.** * **Vomiting/Diarrhea:** If severe vomiting occurs within 2 hours of pill intake, it is treated as a "missed pill."
Explanation: **Explanation:** The most common complication and the most frequent reason for the discontinuation of an Intrauterine Device (IUD), specifically the Copper-T, is **Bleeding (Option A)**. This typically manifests as menorrhagia (increased menstrual flow), metrorrhagia (intermenstrual spotting), or polymenorrhea. The underlying mechanism involves a local inflammatory response in the endometrium, leading to increased vascularity, capillary permeability, and local fibrinolytic activity. **Analysis of Incorrect Options:** * **B. Pain:** This is the second most common complication. It usually occurs as spasmodic dysmenorrhea due to uterine contractions attempting to expel the foreign body. While common, its incidence is lower than bleeding. * **C. Pelvic Infection:** While IUDs slightly increase the risk of Pelvic Inflammatory Disease (PID) within the first 20 days post-insertion (due to the introduction of vaginal flora into the uterus), it is not the most common complication. * **D. Uterine Perforation:** This is a rare but serious iatrogenic complication, occurring in approximately 1 per 1,000 insertions. It most commonly happens during the procedure itself. **High-Yield Clinical Pearls for NEET-PG:** * **Most common cause of removal:** Bleeding and Pain. * **Most common side effect of LNG-IUS (Mirena):** Amenorrhea or oligomenorrhea (unlike Copper-T, which causes bleeding). * **Ideal time for insertion:** During menstruation or within 10 days of the cycle (to ensure the patient is not pregnant and the cervix is slightly dilated). * **Protective effect:** IUDs are known to be protective against endometrial cancer.
Explanation: **Explanation:** The **Levonorgestrel-releasing Intrauterine System (LNG-IUS)**, such as Mirena, works primarily by releasing 20 mcg of levonorgestrel daily directly into the uterine cavity. This causes profound endometrial atrophy and thickening of cervical mucus. **Why "Premenstrual Symptoms" is the correct answer:** Premenstrual Syndrome (PMS) is driven by cyclical hormonal fluctuations (estrogen and progesterone) during the luteal phase of the **ovarian cycle**. Since the LNG-IUS acts locally and does not consistently suppress ovulation, the systemic hormonal shifts responsible for PMS remain largely unaffected. Therefore, it is not a primary treatment for premenstrual symptoms. **Analysis of other options:** * **Menorrhagia:** The LNG-IUS is the "medical gold standard" for idiopathic menorrhagia. It causes thinning of the endometrial lining, leading to a 90% reduction in menstrual blood loss and often resulting in amenorrhea. * **Dysmenorrhea:** By reducing endometrial prostaglandins and decreasing menstrual flow, it significantly alleviates both primary and secondary dysmenorrhea (especially that associated with adenomyosis). * **Pelvic Inflammatory Disease (PID):** The progestogen thickens the cervical mucus, creating a biological barrier that prevents the ascent of pathogens into the upper genital tract, thereby exerting a protective effect against PID. **High-Yield Clinical Pearls for NEET-PG:** * **Life span:** 5 years (Mirena) or 7 years (recent updates). * **Non-contraceptive uses:** First-line for Adenomyosis, Endometrial Hyperplasia (without atypia), and as the progestogen component of Hormone Replacement Therapy (HRT). * **Most common side effect:** Irregular spotting/bleeding during the first 3–6 months. * **Pearl:** Unlike Copper-T, LNG-IUS *decreases* the risk of PID and ectopic pregnancy (though if pregnancy occurs, the *proportion* of ectopics is higher).
Explanation: **Explanation:** The **Calendar Method** (also known as the Rhythm Method) is a traditional form of natural family planning based on the timing of ovulation. It was independently described by **Kyusaku Ogino** (Japan) and **Hermann Knaus** (Austria) in the 1920s. Therefore, it is often referred to as the **Ogino-Knaus Method**. The underlying medical concept is that ovulation occurs approximately **14 days before the onset of the next menstrual cycle**. By tracking the length of previous menstrual cycles, a woman can estimate her fertile window (the days when conception is most likely) and practice abstinence during that period to prevent pregnancy. **Analysis of Options:** * **B. Ogino (Correct):** As mentioned, Ogino identified the relationship between the timing of ovulation and the subsequent menses, forming the basis of the calendar calculation. * **A. Bitings:** This is a distractor. It may be confused with the **Billings Method**, which is the "Cervical Mucus Method" of natural family planning, not the calendar method. * **C. Wallace:** This refers to the "Rule of Nines" used in assessing the percentage of total body surface area in burn patients, unrelated to contraception. * **D. Ogive:** This is a statistical term referring to a cumulative frequency polygon and has no clinical relevance to obstetrics. **High-Yield Clinical Pearls for NEET-PG:** * **Calculation:** To find the fertile period, subtract 18 days from the shortest cycle (first fertile day) and 11 days from the longest cycle (last fertile day). * **Pearl Index:** The failure rate of the calendar method is high (approx. 25 per 100 woman-years with typical use). * **Prerequisite:** It is only reliable for women with regular menstrual cycles. * **Standard Days Method:** A simplified version of the calendar method suitable for women with cycles between 26–32 days (fertile window: Day 8 to Day 19).
Explanation: **Explanation:** Combined Oral Contraceptive Pills (COCPs) primarily function by suppressing ovulation through the inhibition of the Hypothalamic-Pituitary-Ovarian (HPO) axis. **Why Dysmenorrhea is the correct answer:** Dysmenorrhea (painful menstruation) is actually **relieved** by COCPs, not caused by them. Primary dysmenorrhea is mediated by prostaglandins produced during ovulatory cycles. Since COCPs inhibit ovulation and result in a thinner endometrial lining, prostaglandin production is significantly reduced. Consequently, COCPs are a first-line medical treatment for dysmenorrhea and endometriosis. **Analysis of Incorrect Options:** * **Nausea:** This is the most common side effect of COCPs, primarily attributed to the **estrogen** component. It usually subsides after the first few cycles. * **Mastalgia (Breast Tenderness):** This is a common side effect caused by the stimulatory effect of estrogen and progesterone on breast tissue. * **Chloasma (Melasma):** Estrogen stimulates melanocytes, leading to hyperpigmentation of the face (the "mask of pregnancy"). This is more common in women with higher sun exposure. **High-Yield Clinical Pearls for NEET-PG:** * **Most common side effect:** Breakthrough bleeding (spotting), especially in the first 3 months. * **Most common reason for discontinuation:** Breakthrough bleeding. * **Beneficial effects:** COCPs reduce the risk of Ovarian cancer (by 50%), Endometrial cancer (by 50%), and Benign Breast Disease. * **Absolute Contraindications:** History of Thromboembolism (DVT/PE), undiagnosed vaginal bleeding, heavy smokers (>15 cigarettes/day) over age 35, and estrogen-dependent tumors (Breast CA).
Explanation: **Explanation:** The **Irving method** is the correct answer because it is an **open surgical technique** for tubal ligation, not a laparoscopic one. In this procedure, the fallopian tube is cut, and the proximal end is buried into the posterior wall of the uterus, while the distal end is buried in the broad ligament. Due to the extensive tissue mobilization and suturing required, it cannot be performed via a laparoscope. It is known for having the lowest failure rate among all sterilization techniques. **Analysis of other options:** * **Electrocoagulation (Option A):** This was one of the earliest laparoscopic methods. It uses unipolar or bipolar current to thermally destroy a segment of the fallopian tube. * **Falope Ring (Option B):** Also known as the Yoon ring, this is a silastic band applied laparoscopically using a special applicator. It creates a loop of the tube, causing ischemia and eventual fibrosis. * **Filshie Clip (Option D):** This is a titanium clip lined with silicone rubber. It is applied laparoscopically to crush a 3-5 mm segment of the tube. It is popular due to minimal tissue destruction and higher potential for reversibility compared to other methods. **High-Yield Clinical Pearls for NEET-PG:** * **Most common laparoscopic method:** Falope ring (widely used in mass sterilization camps). * **Method with lowest failure rate:** Irving method (Failure rate ~1 in 1,000). * **Method with highest failure rate:** Madlener method (no longer recommended). * **Pomeroy’s Method:** The most common "open" method used during postpartum sterilization (minilap) due to its simplicity and efficacy. * **Bipolar Cautery:** Preferred over unipolar cautery in laparoscopy to prevent accidental bowel burns.
Explanation: **Explanation:** Mifepristone (RU-486) is a synthetic steroid with potent **anti-progestational** and anti-glucocorticoid activity. It acts by competitively binding to progesterone receptors, leading to decidual breakdown and increased uterine sensitivity to prostaglandins. **Why "Induction of Labour" is the correct answer:** While mifepristone increases uterine contractility, it is **not** an approved or standard indication for the induction of labour in a viable pregnancy. Its primary role in late pregnancy is limited to **intrauterine fetal death (IUFD)** to facilitate delivery. For routine induction of labour (live fetus), drugs like Oxytocin and Prostaglandins (Dinoprostone/Misoprostol) are the standard of care. **Analysis of other options:** * **Post-coital contraception:** A single dose of 10 mg mifepristone is highly effective as emergency contraception if taken within 72–120 hours of unprotected intercourse. * **Cervical ripening:** Mifepristone is used pre-operatively (24–48 hours prior) for cervical priming before surgical evacuation or induction of mid-trimester abortion to reduce complications. * **Medical Termination of Pregnancy (MTP):** This is the most common indication. It is used in combination with Misoprostol (Prostaglandin E1) for legal abortion up to 9–10 weeks (63–70 days) of gestation. **High-Yield Clinical Pearls for NEET-PG:** * **MTP Regimen:** 200 mg Mifepristone (oral) followed 36–48 hours later by 800 mcg Misoprostol (vaginal/oral/buccal). * **Other Uses:** Management of Cushing’s syndrome (due to anti-glucocorticoid effect), uterine fibroids, and endometriosis. * **Side Effects:** Heavy bleeding, abdominal cramps, and nausea. * **Contraindication:** Chronic adrenal failure, ectopic pregnancy, and long-term corticosteroid therapy.
Explanation: **Explanation:** The correct answer is **Progestasert**. **1. Why Progestasert is the correct answer:** Progestasert is a first-generation hormone-releasing IUCD that releases progesterone. While all IUCDs significantly reduce the *absolute* risk of all pregnancies (including ectopic), if a pregnancy does occur with an IUCD in situ, the *relative* risk of it being ectopic is higher. Progestasert carries the highest risk among all IUCDs because progesterone **decreases fallopian tube motility** and slows down ciliary action. This delay in the transport of the fertilized ovum through the tube increases the likelihood of implantation within the tube rather than the uterus. **2. Why the other options are incorrect:** * **Lippes loop (Option B):** A non-medicated (inert) IUCD. While it has a higher failure rate than medicated IUCDs, it does not specifically alter tubal motility to the extent that hormonal devices do. * **Copper-T and Multiload (Options C & D):** These are medicated copper-releasing IUCDs. Copper acts primarily as a spermicide and causes a sterile inflammatory response in the endometrium. While they can be associated with ectopic pregnancy if they fail, the risk is significantly lower than with progesterone-only devices. **High-Yield Clinical Pearls for NEET-PG:** * **Highest Ectopic Risk:** Progestasert (Progesterone-releasing). * **Lowest Ectopic Risk:** LNG-20 (Mirena) actually has a lower absolute risk of ectopic pregnancy compared to women using no contraception, because it is highly effective at preventing conception altogether. * **Mechanism:** Progesterone = Decreased tubal motility; Copper = Spermicidal/Inflammatory. * **Most Common Site of Ectopic Pregnancy:** Ampulla of the Fallopian tube. * **Key Fact:** The most common cause of ectopic pregnancy overall is Pelvic Inflammatory Disease (PID), but among IUCD failures, Progestasert carries the highest relative risk.
Explanation: **Explanation:** The core concept tested here is the distinction between **Long-Acting Reversible Contraception (LARC)** and **Permanent Methods** of sterilization. **Why Option B is correct:** Laparoscopic tubal sterilization is a **permanent surgical method** (permanent contraception). While technically it can sometimes be reversed through microsurgery, it is intended to be irreversible and is not classified under the LARC category. LARCs are defined by two criteria: they last for an extended period (3–10 years) and are **immediately reversible** upon removal with a rapid return to baseline fertility. **Why other options are incorrect:** * **Option A (Copper T):** This is a non-hormonal LARC. Depending on the model (e.g., CuT 380A), it provides highly effective protection for up to 10 years. * **Option C (Implanon):** This is a progestogen-only subdermal implant. It is a LARC that provides protection for 3 years. * **Option D (LNG-IUD):** Also known as Mirena, this is a hormonal LARC. It is effective for 5–8 years and is also used for managing Menorrhagia. **High-Yield Clinical Pearls for NEET-PG:** * **LARC "Tier 1" Effectiveness:** LARCs are as effective as sterilization (failure rate <1%) because they eliminate "user error." * **Ideal Candidate:** LARCs are now recommended as first-line options for both nulliparous and multiparous women, including adolescents. * **Quick Start:** Most LARCs can be inserted at any time during the menstrual cycle if pregnancy is reasonably excluded. * **Failure Rates:** The typical use failure rate of CuT 380A is ~0.8%, while for Implanon, it is ~0.05% (making it the most effective reversible method).
Natural Family Planning Methods
Practice Questions
Barrier Methods
Practice Questions
Hormonal Contraceptives
Practice Questions
Intrauterine Devices
Practice Questions
Emergency Contraception
Practice Questions
Permanent Contraception Methods
Practice Questions
Contraception in Special Populations
Practice Questions
Contraceptive Counseling
Practice Questions
Side Effects and Complications of Contraceptives
Practice Questions
Future Contraceptive Technologies
Practice Questions
Get full access to all questions, explanations, and performance tracking.
Start For Free